Botulinum Toxin A Injections for Reduction of Facial Rhytids

  • Sharon D. Gertzman


Botulinum Toxin A, commonly known as Botox® or Botox® Cosmetic (both: Allergan, Irvine, CA) or Dysport (Medicis, USA), is a neurotransmitter blocker that is used in aesthetic procedures to erase the fine lines of the face known as active lines. The mechanism of action of this drug is to block neurotransmitters in the facial muscles by binding the muscle receptor site on the muscles necessary to make the muscle fire. Botox® or Botox® cosmetic take approximately 2–7 days to work their way into the muscle and remain tightly bound to the muscles for approximately 3–5 months, whereas Dysport takes effect in 1.5 days and remains effective for 4–6 months. Botox has been available for use in the US since the early 70s. Dysport was approved for cosmetic use by the FDA in 2009. It has however, been in use for cosmetic purposes in Europe under the trade name Reloxin for approximately 20 years.


Botulinum Toxin Facial Muscle Gauge Needle Active Line Frontalis Muscle 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin A in the treatment of glabellar rhytids in females. Dermatol Surg 2005;31:414–422.PubMedCrossRefGoogle Scholar
  2. 2.
    Hexsel DM, Trinidad De Almeida A, Rutowitsch M, Alencar De Castro I, Silveria VLB, Gobatto DO, Zechmeister M, Mazzuco R, Zechmeister D. Multicenter, double-blind study of the efficacy of injections with botulinum toxin A reconstituted up to six consecutive weeks before application. Dermatol Surg 2003;29:523–529.PubMedCrossRefGoogle Scholar
  3. 3.
    Brandt F, Swanson N, Baumann L, A phase III, randomized double blind, Placebo-Controlled study to assess the efficacy and safety of reloxin® in the treatment of glabellar lines. Presented at the 31st Hawaii dermatology seminar March 3–9, 2007 Maui, HI.Google Scholar
  4. 4.
    Moy R, Maas C, Monheit G, Huber B, Reloxin investigational group. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg. 2009;11:77–83.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Serenity Medical SpaPenningtonUSA

Personalised recommendations